PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2023 Financial ResultsPRNewsWire • 07/20/23
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against PTC Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 07/19/23
PTC Therapeutics Co-Founder Allan Jacobson, Ph.D., Awarded 2023 Gruber Genetics PrizePRNewsWire • 07/19/23
PTC Therapeutics Appoints Experienced Healthcare Finance Strategist Pierre Gravier as Chief Financial OfficerPRNewsWire • 07/17/23
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against PTC Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 07/13/23
PTC Therapeutics Announces Virtual Presentation on Phenylketonuria (PKU) and SepiapterinPRNewsWire • 07/11/23
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against PTC Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 07/11/23
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against PTC Therapeutics, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the FirmAccesswire • 07/08/23
PTC Therapeutics Announces Results from MIT-E Clinical Trial of Vatiquinone for the Treatment of Mitochondrial Disease Associated SeizuresPRNewsWire • 06/29/23
PTC Therapeutics Shares Positive Interim Data from PIVOT-HD Clinical Trial in Huntington's Disease PatientsPRNewsWire • 06/21/23
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against PTC Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 06/04/23
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against PTC Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmBusiness Wire • 05/24/23
PTC Therapeutics Takes Investors On A Ride With A Failed Study, Scrapped Programs, Ousted CFOInvestors Business Daily • 05/23/23
PTC Therapeutics Announces Topline Results from Vatiquinone MOVE-FA Registration-Directed TrialPRNewsWire • 05/23/23
Why PTC Therapeutics Could Be Victorious In Its Rare-Disease Battle Against BioMarin PharmaceuticalsInvestors Business Daily • 05/17/23
PTC Therapeutics Announces APHENITY Trial Achieved Primary Endpoint with Sepiapterin in PKU PatientsPRNewsWire • 05/17/23
PTC Therapeutics Provides a Corporate Update and Reports First Quarter Financial ResultsPRNewsWire • 04/27/23
PTC Therapeutics (PTCT) Upgraded to Buy: What Does It Mean for the Stock?Zacks Investment Research • 04/27/23